Star Sports Medicine Co (1609) Fair Value & Analysis
Healthcare · HK · Market cap HK$8.5B
Fair value as of: Aug 5, 2026
From 24 valuation models · updated 5 days ago
Fair value updated Aug 5, 2026, revised from HK$54.81 to HK$51.20 (−6.6%) since Jul 2, 2026. Share price −22.8% over the past month.
A solid business, but screening 60% overvalued on our models.
What matters now
- A high-quality business (quality 74/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (HK$63.48). The favourable scenario is already priced in.
Price vs Fair Value (3 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 5, 2026.
How to read this chart
3‑month range HK$113.00 – HK$218.40 · fair‑value band HK$38.92 – HK$63.48 · the HK$129.30 price screens above the HK$51.20 fair value. As of Aug 5, 2026.
Analysis
Star Sports Medicine Co (1609) currently trades at HK$129.30, while our model-based Fair Value estimate is HK$51.20, implying the stock looks roughly 60.4% overvalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Star Sports Medicine Co generated revenue of HK$403M at a net margin of 34.0%. It earns a return on equity of 25.4%. The stock trades on a trailing P/E of 53.8. Fundamentals as of Aug 5, 2026
Our scenario range runs from HK$38.92 (bear case) to HK$63.48 (bull case); at HK$129.30, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -60%, 1609 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (HK$102.09) versus Asset-Based (HK$7.45). Highest evidence: Growth DCF (80).
Key figures & financial health
Figures from reported company fundamentals · as of Aug 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 75 · Market factors (momentum, volatility) 2
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon fiber reinforced PEEK suture anchor; interference screws and sheath fixation system, bioabsorbable …
Full company description
Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon fiber reinforced PEEK suture anchor; interference screws and sheath fixation system, bioabsorbable interference screw, bioabsorbable interference screws and sheath fixation system, PEEK screws and sheath fixation system, and PEEK composite interference screw; suture buttons and high-strength sutures, such as adjustable suture button, fixed suture button, ultra-high molecular weight polyethylene(UHMWPE) suture; meniscus repair systems, all-suture meniscus repair system, accurFix all-inside meniscus repair system, and multi-needle and flexible meniscus repair system. The surgical equipment and associated medical consumables, includes plasma RF ablation equipment, arthroscopic surgical shaver, arthroscopic camera system, and disposable shaver blade plasma electrode. Its other products includes disposable PRP preparation kit, desktop centrifuge. The company also provides biomaterial platform, imaging and dynamic platform, intelligent medicine platform, and tissue engineering platform. The company was founded in 2017 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Star Sports Medicine Co reported revenue of HK$403M in FY2025 versus HK$147M in FY2022, a compound +40.1%/yr. Reported net income was HK$137M in FY2025, compounding +50.3%/yr from FY2022.
1609 screens 60% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Star Sports Medicine Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Star Sports Medicine Co (1609) overvalued or undervalued?
What is the fair value of 1609?
What is the quality score of 1609?
What is the revenue of Star Sports Medicine Co (1609)?
What is the net profit margin of 1609?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Star Sports Medicine Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.